The expanded agreement aims to deliver greater cost leadership and productivity enhancement for Gilead while seeking to extract greater value from the existing relationship. Leveraging machine ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

A new chief executive trying to steer the company, generative AI disrupting the information technology (IT) services industry, and now an activist shareholder raising its stake—New Jersey-based ...

Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

Medical pioneer Gilead Sciences GILD has seen its stock etch out new 52-week highs as the broader market pulled back sharply in recent weeks. Gilead has joined Johnson & Johnson JNJ, and a cluster ...

Cognizant shares now trade at around $83 per share, giving the company a market value of more than $41 billion.

Gilead Sciences has a 52-week low of $62.07 and a 52-week high of $117.39. The firm’s 50 day moving average is $99.15 and its 200-day moving average is $91.09.

Valued at a market cap of $143.8 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need.

Kennet Brysting, president of Gilead Sciences Japan, mentioned an intriguing possibility during an interview in Tokyo late last year. “I do believe that Japan could be one of the first countries ...

The latest analyst rating for Gilead Sciences (NASDAQ:GILD) was provided by Morgan Stanley, and Gilead Sciences maintained their overweight rating. The last upgrade for Gilead Sciences Inc ...

Weeks after settling a five-year patent dispute with the U.S. government for an undisclosed sum, California's Gilead Sciences revealed that it has set aside $200 million for a potential resolution ...